Evidence map›Paper›PMID 10852966›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2000

The X-linked lymphoproliferative syndrome gene product SH2D1A associates with p62dok (Dok1) and activates NF-kappa B.

B S Sylla, K Murphy, E Cahir-McFarland, W S Lane, G Mosialos, E Kieff

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Diacylglycerol Kinase alpha in X Linked Lymphoproliferative Disease Type 1.International journal of molecular sciences · 2021
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. IkappaB kinase beta phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation.Proceedings of the National Academy of Sciences of the United States of America · 2004
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

B S SyllaDepartments of Medicine and Microbiology and Molecular Genetics, Brigham and Women's Hospital and Harvard University, 181 Longwood Avenue, Boston, MA 02115; and Microchemistry Facility, Harvard University, 16 Divinity Avenue, Cambridge, MA.
K Murphy
E Cahir-McFarland
W S Lane
G Mosialos
E Kieff
Brigham and Women's Hospital · USHarvard University · US

Funding

Epstein-Barr Virus Nuclear Proteins in B Cell Growth TransformationR01CA047006 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHAO, BO · 2002 to 2021
$12.1M
MOLECULAR BIOLOGY OF EPSTEIN-BARR VIRUS INFECTIONR35CA047006 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KIEFF, ELLIOTT D · 1987 to 2000
$1.6M
SIGNAL TRANSDUCTION BY THE EBV TRANSFORMING PROTEIN LMP1R29CA071705 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MOSIALOS, GEORGE · 1996 to 1999
–
NCI NIH HHS CA47006NCI NIH HHS CA71705NCI NIH HHS R01 CA047006NCI NIH HHS R35 CA047006
6 · The paper itself

Abstract

The X-linked lymphoproliferative syndrome (XLP) is a genetic disorder in which affected males have a morbid or fatal response to Epstein-Barr virus infection. The XLP deficiency has been mapped to a gene encoding a 128-residue protein, SH2D1A, which is comprised principally of a Src homology 2 (SH2) domain. We now report that SH2D1A associates with Dok1, a protein that interacts with Ras-GAP, Csk, and Nck. An SH2D1A SH2 domain mutant that has been identified in XLP does not associate with Dok1, in accord with the hypothesis that this interaction is linked to XLP. The association of SH2D1A with Dok1 also depends on phosphorylation of Dok1 Y(449) in the sequence ALYSQVQK. Further, overexpression of SH2D1A is found to activate NF-kappaB in 293T cells. NF-kappaB activation by SH2D1A does not depend on the wild-type SH2 domain and is inhibited by a dominant-negative IkappaB kinase beta. Thus, SH2D1A can affect multiple intracellular signaling pathways that are potentially important in the normal effective host response to Epstein-Barr virus infection.

Indexed as

DNA-Binding ProteinsIntracellular Signaling Peptides and ProteinsRNA-Binding ProteinsCarrier ProteinsEpstein-Barr Virus InfectionsGene Expression RegulationGenetic Predisposition to DiseaseHumansLymphoproliferative DisordersMaleNF-kappa BPhosphoproteinsSignaling Lymphocytic Activation Molecule Associated ProteinSyndromeTumor Cells, CulturedX ChromosomeCarrier ProteinsDNA-Binding ProteinsDOK1 protein, humanGAP-associated protein p62Intracellular Signaling Peptides and ProteinsNF-kappa BPhosphoproteinsRNA-Binding ProteinsSH2D1A protein, humanSignaling Lymphocytic Activation Molecule Associated Protein

Identifiers

PMID10852966
PMCPMC16569
OpenAlexW1991257124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.